News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mirna Therapeutics, Inc.Announces First Patient Enrolled In Hematological Malignancy Cohort Of Its Phase 1 Clinical Trial


6/10/2014 10:00:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AUSTIN, Texas--(BUSINESS WIRE)--Mirna Therapeutics, Inc. (Mirna), a clinical-stage biopharmaceutical company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the enrollment of the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34, the company’s lead product candidate and first microRNA mimic in human clinical trials in oncology.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES